Aeolus Pharmaceuticals (OTCQB: AOLS) is developing a platform of novel therapeutics for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed as a medical countermeasure for the pulmonary effects of acute radiation syndrome and delayed effects of acute radiation exposureunder a contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the United States Department of Health and Human Services (“HHS”). The total value of the contract with all options is $118.4 million, according to the company’s website (see here: www.AOLSRX.com). SNNLive caught up with David Cavalier, Chairman & CFO of Aeolus Pharmaceuticals, Inc., at the LD Micro Invitational 2016 in Bel Air, CA.
In this video interview, Mr. Cavalier and our host discuss the following topics:
- Overview of Aeolus Pharmaceuticals, Inc.
- Discusses development contract with U.S. government
- Clinical Development
- Pipeline programs in Parkinson’s and infectious disease
- History of the technology
- Milestones for 2016-2017
- Mr. Cavalier’s background
For more information about Aeolus Pharmaceuticals, Inc., please visit: www.AOLSRX.com
The interview may contain forward-looking statements about Aeolus Pharmaceuticals, Inc. See Aeolus Pharmaceutical's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions